AbbVie-backed ADARx said it is planning an IPO to fund its pipeline of clinical-stage siRNA programs. The company positioned the proposed offering as a way to bankroll ongoing clinical studies spanning multiple next-generation RNAi assets, with a focus on advancing through key development milestones. The move signals renewed appetite for platform-driven RNA therapeutics as investors look for differentiated mechanisms and clearer late-stage development traction. It also highlights how larger strategic backers, such as AbbVie, continue to underwrite risk in early and mid clinical stages. For the sector, ADARx’s IPO plans add to the competitive landscape for siRNA developers seeking capital intensity to sustain multiple trials and expansion of manufacturing and translational work.